← Leaderboards
Gary A Koppel
Azevan Pharmaceuticals, Inc.
$2,945,305
Attributed
$2,945,305
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $801K · FY2005–08$1M$750K$500K$250K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$2,945,305 · 1
By mechanism
R44$2,945,305 · 1
Top collaborators
No co-investigators on record.
Most similar at Azevan Pharmaceuticals, Inc.
Same institution · by research overlap
- Michael J Brownstein$9,854,619
- Eve Marie Damiano$1,021,700
- Neal Gordon Simon$141,071
Others in their field
Top investigators on “Drug Screening /Evaluation”
- Fred M Gordin · Social And Scientific Systems, Inc.$68,001,399
- John C S Breitner · Johns Hopkins University$33,065,187
- Philip J Disaia · University Of California Irvine$21,551,991
- George R Painter · Chimerix, Inc.$19,230,662
- Gregory H Reaman · National Childhood Cancer Foundation$17,052,970
- Stephen J Durako · Westat, Inc.$15,048,684
Research focus
Drug Screening /EvaluationAdverse EffectsAdministration, OralDrug Design /Synthesis /ProductionAmericanAnimal ModelAdrenal GlandsAffectAffinityAnxietyBackBaseBiological AvailabilityBiologyAnti-Anxiety AgentsChronicChronic StressClassClinical Trials, Phase IAntidepressive AgentsCommercializationConditionDepressed MoodEconomic Burden
Grant awards (5)
A Potential New Drug for Depression$797,078
R44 · FY2008 · MH · contact PI
A Potential New Drug for Depression$801,007
R44 · FY2007 · MH · contact PI
A New Drug for Depression$449,093
R44 · FY2006 · MH · contact PI
A New Drug for Depression$449,073
R44 · FY2005 · MH
A New Drug for Depression$449,054
R44 · FY2004 · MH